Abstracts tagged "prognostic factors and rheumatic disease"

Abstract Number: 1791 • 2013 ACR/ARHP Annual Meeting
Reaching The Target Of Low Disease Activity At 6 Months Predicts Better Long-Term Functional Outcome In Patients With Early Rheumatoid Arthritis
Pooneh Akhavan¹, Bindee Kuriya², Edward C. Keystone^3,4, Juan Xiong⁵, Janet E. Pope⁶, Gilles Boire⁷, Diane Tin⁸, Boulos Haraoui⁹, Carol A. Hitchon¹⁰ and Vivian P. Bykerk^11,12, ¹Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁵Mount Sinai Hospital, Toronto, ON, Canada, ⁶St Joseph Health Care, London, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ¹⁰Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ¹²Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Current clinical practice guidelines recommend remission, and if not possible, low disease activity (LDA) as the treatment target in rheumatoid arthritis (RA). Patients should…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].